Unified, holistic medical data collection and analysis platform

Informazioni relative al progetto

UNITY

ID dell’accordo di sovvenzione: 868266

DOI

10.3030/868266

Progetto chiuso

Data della firma CE 30 Aprile 2019

Data di avvio 1 Maggio 2019

Data di completamento 31 Agosto 2019

Finanziato da

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

RAYLYTIC GMBH
Germany

Periodic Reporting for period 1 - UNITY (Unified, holistic medical data collection and analysis platform)

Periodo di rendicontazione: 2019-05-01 al 2019-08-31

Sintesi del contesto e degli obiettivi generali del progetto

UNITY is a cloud-based platform that combines modules for clinical trial management, electronic data capture of patient reported and treatment outcomes, and semi-automated medical image analysis. Its image analysis module can assess the performance of orthopedic implants and detect and quantify musculoskeletal conditions with an accuracy superior to human radiologists. However, we are constrained by our semi-automatic way of processing medical images. Once we develop a fully automated platform, it will be able to perform in seconds tasks that now may take up to one week. With individual modules already on the market and a prototype of the UNITY platform in place, our technology is at TRL 6.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

The feasibility study was conducted to validate our idea of deploying UNITY as fully automated platform for assessment of musculoskeletal conditions. We assessed the technical requirements and prepared a work plan that served as basis for estimating the resources and time needed to complete the project. We also performed a comprehensive analysis of the market, including competition, challenges and trends, freedom to operate and size of the market opportunity. Finally, we developed a business plan for its commercialization; it outlines the strategy to grow our market share and customer base, as well as tentative pricing and revenue models.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

The expected impact of the Accelerator grant to our company is very high: we project revenues growing up to €26.4 million in the first 5 commercialization years. We also forecast a growth from 25 to 54 employees and a return on investment of 5.7 by the end of 5th commercialization year.
Our platform offers a unique opportunity for more accurate, personalized treatments. This can result in savings and optimization of workflows for healthcare providers and medtech companies, currently challenged with increasing regulatory constraints. It can also improve the quality of care benefiting both, the patients and the economy.

image-1.png